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Abstract
Background: Hepatic angiosarcoma (HAS) is a rare type of liver cancer that is often fatal, and arsenic and vinyl
chloride monomer (VCM) are two major causal agents. Whereas Taiwan is an endemic area of liver cancer,
epidemiologic data on HAS are limited. We reviewed the cases observed at a teaching hospital to evaluate the
roles of VCM, arsenic, and viral hepatitis in the occurrence of HAS.
Methods: We reviewed the medical records of patients with pathological proof of HAS from January 2000 to
August 2010 at a teaching hospital which is adjacent to the major VCM processing area in Taiwan and nearby an
endemic area of arsenic exposure from drinking water. We also conducted a literature review and included all
patients of HAS reported in Taiwan.
Results: Six male and three female cases aged from 56 to 83 years (64.6 ± 8.2 years) were identified at the
hospital. The differences in clinical features between men and women were not statistically significant. None of
them had exposure to VCM or arsenic in drinking water. Two had evidence of hepatitis C infection, but none had
evidence of hepatitis B infection. Five male and four female cases aged 30 to 82 years (58.6 ± 15.5 years) were
identified in the literature, including two with arsenic exposure and one with chronic hepatitis B infection.
Conclusions: HAS is rare in Taiwan, and we found no evidence supporting a major role of VCM, arsenic in drinking
water, or viral hepatitis in its occurrence.
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Background
Hepatic angiosarcoma (HAS) is a rare type of liver can-
cer, and some studies showed that it is related to
arsenic, vinyl chloride monomer (VCM), thorium diox-
ide (Thorotrast), and radium [1-4]. HAS accounts for
only 2% of hepatic malignancy in west countries [1,5,6],
but epidemiological data in Asia are very limited,
although liver cancer is relatively prevalent in this area.
Many cases of HAS are asymptomatic when they are
diagnosed accidently, and the most common initial com-
plaints are nonspecific symptoms such as right upper
quarterant pain, fatigue, weakness, and weight loss [1],
making it rarely diagnosed antemortem [1,7].
HAS is of special interest to occupational medicine
due to its correlations to vinyl chloride monomer
(VCM) and other industrial chemical exposures such as
arsenic pesticides in vineyard workers [7]. It is also
related to arsenic exposures from other sources such as
Fowler’s solution to treatment of certain diseases [8,9]
and drinking water containing high level of arsenic
[3,10]. In some cases, HAS was reported in patient
under hemodialysis (HD) [3,4] or with congestive heart
failure [11].
Taiwan (Republic of China; R.O.C.) has been a major
polyvinyl chloride (PVC) producer in the world for dec-
ades and has several endemic areas of arsenic exposure
from drinking water. In addition, it is an endemic area
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any medium, provided the original work is properly cited.of liver cancer due to the high prevalence of viral hepa-
titis. However, there are limited reports about HAS in
Taiwan. We conducted a study to evaluate the roles of
VCM, arsenic, and viral hepatitis in the occurrence of
HAS in Taiwan.
Methods
Identification of patients at a teaching hospital
This study was conducted at Kaohsiung Veterans Gen-
eral Hospital in Kaohsiung in collaboration with the
National Cheng Kung University in Tainan. We
reviewed the medical records of patients who were diag-
nosed as having HAS through pathological examination
of specimens obtained by fine-needle aspiration (FNA)
or surgical procedures from January 2000 to August
2010. This 1330-bed hospital is adjacent to the major
PVC production area in Taiwan and nearby an endemic
area of arsenic exposure from drinking water generally
known as the blackfoot diseases endemic area [3]. From
each patient, we collected data on demographic charac-
teristics, medical history, hemogram, biochemistry, mar-
kers of hepatitis B (HBV) and C (HCV) virus infections,
markers associated with hepatic tumor, and clinical
course. In addition, we collected information of serial
image studies using sonography, magnetic resonance
imaging (MRI), and computed tomography (CT), which
included tumor size and location. We also collected
information on occupational history and environmental
exposures, including underground water drinking. The
study protocol was approved by the Human Research
Committee of the hospital.
Identification of cases in the literature
In order to identify cases of HAS reported in Taiwan,
we also conducted a thorough literature search in the
PubMed database using “angiosracoma” as the key word
and review the articles retrieved. Further search of lit-
erature was conducted through reviewing the references
listed in retrieved articles.
Statistical analyses
We performed statistical analyses using SPSS software
for Windows (Version 12; SPSS Inc., Chicago, IL, USA).
All data were expressed as mean ± standard deviation,
and the differences between two groups were evaluated
using the Mann-Whitney U test for continuous variables
and Fisher’s exact test for categorical variables. A p
value of less than 0.05 was considered to be statistically
significant.
Results
Nine patients (six men, three women) of HAS were
identified at the hospital during the study period (Table
1). The average duration of follow-up was 14 months,
and two patients died within 3 months (Table 1). Eight
of the nine patients had bilateral lobes involvement, and
all had multiple segments invasion. In some patients,
abdominal CT revealed contrast enhanced lesions per-
sistently, while in the others it showed hypo-attenuated
lesions in the venous phase (Figure 1). The diagnosis
was made on the basis of FNA in five patients and sur-
gery in four. Histological examination showed focal vas-
cular channels lined by atypical cells with positive
staining for at least one of the following markers: CD31,
CD 34, or factor VIII (Table 2) (Figure 2). The age at
diagnosis ranged from 56 to 83 years (64.6 ± 8.2 years),
and it was similar between men (64.8 ± 10.0 year) and
women (64.0 ± 4.6 year) (p = 0.80) (Table 2). None of
the differences in other characteristics reached statistical
significance.
Two patients received transarterial embolization
(TAE), including one receiving operation after the TAE
due to liver rupture and the other receiving hepatic
arterial infusion chemotherapy (HAIC) after the TAE.
Of the four patients who received operation, three
developed multiple metastases afterwards with post-
operative chemotherapy, including one with radiother-
apy simultaneously and another suffering from liver rup-
ture (Table 1). Four patients received conservative
treatment only. The difference in the maximum tumor
size between men (8.9 ± 3.4 cm) and women (13.5 ± 7.1
cm) did not reach statistical significance (p = 0.51)
(Table 2), and the two patients who suffered from liver
rupture had the largest and the third largest tumor sizes
(18.5 and 10.7 cm, respectively).
Four of the patients had diabetes mellitus, including
three with hypertension, and two non-diabetic patients
also had hypertension. Only one patient had a concur-
rent tumor, which was a gastrointestinal stromal tumor
(Table 1). At diagnosis, the chief complaint included
liver tumor in four patients (44.4%), abdominal pain in
three (33.3%), and non-specific complaint in two (22.2%)
(Table 1). The hemogram and biochemistry data
revealed no differences between men and women (all p
values > 0.05) except that white blood cell counts were
higher in women (p = 0.02), which was attributed to
one with liver rupture and another with a concurrent
tumor (GIST) and metastasis (Table 3). Three diabetic
men and one woman had high blood sugar levels, and
the hemodialytic woman was the only patient with ele-
vated serum creatinine and total bilirubin. Other hemo-
gram and biochemistry data were within normal limits
(Table 3). All patients had normal values of tumor mar-
kers associated with hepatic tumor, including alfa-feto-
protein (AFP), carcinoembryonic antigon (CEA), and
carbohydrate antigen 19-9 (CA199).
None of the patients was a HBV carrier, but two had
HCV infection, including a uremic patient under
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habit, and one of them was recognized as alcoholism
who had liver cirrhosis (Table 1). As to occupational
history, only the woman HCV carrier under mainte-
nance HD had contact with PVC at work, which was
during the manufacture of plastic products, but none of
the patients had occupational exposure to VCM,
radium, or arsenical pesticides. Furthermore, none of
the patients recalled exposure to thorium dioxide or
using Fowler’s solution, and none of them have ever
lived in the BFD area, where the underground water had
high levels of arsenic.
We reviewed the literature on HAS in Taiwan and
found nine more patients (five men, four women) of
HAS, and the age at diagnosis ranged from 30 to 82
years (58.6 ± 15.5 years)[3,12-19] (Table 4). Only one
patient had hepatitis B infection. The differences in the
mean age at diagnosis, male-to-female ratio, and sero-
prevalence rates of HBV and HCV infection between
our cases and cases reported in the literature did not
Table 1 Clinical features of patients of hepatic angiomyosarcoma
Case Sex Age
(year)
Chief
Complaint
Comobidity Alcohol
Drinking
Hepatitis Treatment Metastasis Follow-
up
Immunostaining
1 M 65 liver tumor DM yes none C none 3 M CD31, Factor VIII
2 M 62 abdominal
pain
HTN, gout No none C none 1 W CD31, vimentin
3 M 67 right
subcostal
pain
DM, HTN No none OP+C/T lung, subphrenic,
peritoneum
44 M CD31, CD34, Factor VIII,
FLI-1, vimentin,
4 F 69 general
weakness
DM, HTN, gastric
GIST
No none OP+C/T
+R/T
brain, spine 37 M CD31
5 M 83 general
edema
HTN, CAD,
COPD
No none C none 8 M CD31
6 M 56 epigastric
mass
DM, HTN, liver
rupture
No none TAE+OP none 4 M CD31
7 F 60 liver tumor hypothyroidism,
uremia
No HCV C none 2 M CD34
8 F 63 right
abdominal
pain
liver rupture No none OP+C/T peritoneum,
duodeum, colon
3 M CD31
9 M 56 liver tumor L/C, EV, left hip
AVN
yes HCV TAE+HAIC none 24 M CD31, CD34, D2-40, c-kit,
Factor VIII
DM = diabetes mellitus; HTN = hypertension; GIST = gastrointestinal stromal tumor; CAD = coronary arterial disease; COPD = chronic obstructive pulmonary
disease; L/C = liver cirrhosis; EV = esophageal varies; AVN = avscular necrosis; OP = operation; TAE = transarterial embolization; C/T = chemotherapy;C=
conservative treatment; HAIC = hepatic arterial infusion chemotherapy; M = month; W = week.
Figure 1 The abdominal computed tomograph in a patient of hepatic angiosarcoma (Case 9). A low-density mass (3.5 cm) with persistent
contrast enhancement (29/54/68 hu) in left hepatic lobe is noted (arrowhead) (left: non-contrast phase, right: venous phase). Several enhancing
lesions (1-3 cm) in right lobe of liver S5 are not well demonstrated in the venous phase (not shown in figure). Irregular liver surface,
splenomegaly, and collateral circulation are noted, indicating cirrhosis.
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sures, only one had chronic exposure of arsenic pesti-
cide. One of the patients had diabetes mellitus, one had
hypertension, and one had uremia under maintenance
HD. At diagnosis, the chief complaints included abdom-
inal pain or fullness in four patients (44.4%), liver tumor
in three (33.3%), lower back pain in one (11.1%), and
fever in one (11.1%) (Table 4). Three of the patients
received operation and TAE, one received operation,
and one received TAE. Three patients had liver rupture,
including one with operation and TAE, one with opera-
tion, and one with conservative treatment. Metastasis
was observed in two patients, including one in the
spleen and the other in the L2 spine.
Discussion
HAS is rare, but is the most common malignant
mesenchymal tumor of liver [1,5,6,20-22]. A study in
the New York State found an annual incidence of 0.26
per million [23], and another study estimated that the
mortality rate was 0.075 cases per million population
per year in the Unites States and that there were about
17 cases each year in the whole country [2]. In Western
countries, it occurs more frequently in men with a
male-to-female ratio of about 3:1 to 4:1, and most fre-
quently in the sixth to seventh decades of life [1,2,7]. In
Taiwan, an analysis of data from the National Cancer
Registry Program from 1981 to 1999 found only 26
patients, and the male-to-female ratio was 1.9:1 [3],
which is close to our finding of 2.0:1, but much lower
than the 3:1 ratio in hepatic carcinoma (HCC) [24]. A
study in Shanghai, People’s Republic of China (PRC)
[25] found 6 cases of HAS in 5,487 consecutive cases of
primary liver cancers from 1991 to 2005, which was
higher than the proportion of 8 in the 40,832 cases
from 1980 to1999 in a study in Taiwan [24]. The Shang-
hai study reported a male-to-female ratio of 2.0:1, so did
a study of 6 consecutive cases of HAS from 2000 to
2005 in Ganzhou, PRC [26]. The male-to-female ratio in
the Chinese population appears to be quite consistent
across studies and is lower than those reported in the
Western countries.
While the most common presenting symptoms of
HAS were reported to be abdominal pain and non-spe-
cific systemic complaints such as weakness, fatigue,
weight loss, and anorexia that appear in 25-50% patients
[1,7], we found that a substantial number of patients
Table 2 Demographic data on patients of hepatic
angiomyosarcoma
Men Women p value
Number of patients 6 (66.7%)
a 3 (33.3%)
a
Max. tumor size (cm) 8.9 ± 3.4 (3.9-13.5) 13.5 ± 7.1 (8.4-18.5) 0.51
Age (year) 64.8 ± 10.0 (56-83) 64.0 ± 4.6 (60-69) 0.80
Pathology 0.52
FNA 4 1
Surgery 2 2
Treatment 0.45
Operation 1 0
OP+C/T 1 1
OP+C/T+R/T 0 1
TAE+HAIC 1 0
TAE+OP 1 0
Conservative 3 1
Metastasis 1 2 0.23
Liver rupture 1 1 > 0.95
Hepatitis > 0.95
HCV 1 1
Alcohol drinking 2 0 0.50
Uremia in HD 0 1 0.33
All data of tumor size and age expressed as mean ± standard deviation; FNA
= fine needle aspiration; OP = operation; C/T = chemotherapy; R/T =
radiotherapy; HAIC = hepatic arterial infusion chemotherapy; TAE =
transarterial embolization; HCV = hepatitis C virus; HD = hemodialysis.
aData express as percentage (%) of all patients.
Figure 2 The pathological features of hepatic angiosarcoma (Case 9). The sections of the specimen show a picture of liver tissue with
sheets of spindle tumor cells with focal necrosis (Left, H&E stain, x200). Focal vascular channels are also lined by atypical cells. The tumor cells
show positive staining in the CD31 (Right, x200), CD34, factor VIII, D2-40 and c-kit stains, and negative for AE1/AE3, hepatocyte, S100, and HHF-
35 stains.
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health examinations, highlighting the importance of per-
iodical health check-ups. Hepatomegaly with ascites,
jaundice, and splenomegaly are the most common find-
ings on physical examination [7]. Of the 18 cases in this
series, one patient identified at the hospital and one pre-
viously reported case in Taiwan had uremia, and one of
them had history of HCV infection [3], which is similar
to a case reported in Japan [4].
Spontaneous liver rupture is not uncommon and
associates with high mortality and morbidity rates,
which presents with intra-abdominal bleeding occurring
in 27% of HAS patients [1]. Five patients of HAS with
liver rupture, including two in our series and three in
Table 4 Previously reported cases of hepatic angiomyosarcoma in Taiwan
Reference Sex Age
(year)
Chief Complaint Comobidity Alcohol
Drinking
Hepatitis Treatment Metastasis Follow-
up
Immunostaining
Weng et
al. [12]
M 42 fever none no none TAE+OP none 7 M Factor VIII, UEA-I,
vimentin,
Tsai et al.
[13]
M 56 liver tumor RA, OA knees, liver
rupture
no HBV C spleen 9 W Factor VIII, UEA-I,
vimentin, CD34
Tsai et al.
[14]
M 30 epigastralgia,
general weakness
None no none TAE+OP none 17 D NA
Liang et
al. [15]
F 59 liver tumor none no none OP none 24 M Factor VIII,
vimentin
Tsai et al.
[16]
M 60 dyspnea, abdominal
pain
DM, liver rupture no none TAE none 24 D NA
Hsiao [17] F 82 abdominal fullness,
abdominal pain,
nausea
HTN, CRI, PUD, L/C no none none none 42 M CD34
Ho et al.
[3]
F 68 abdominal pain uremia in HD, HTN,
ureteral papilloma, liver
rupture
no none OP+TAE
+R/T
spine 42 M Factor VIII
Hsu [18] M 72 lower back pain aortic aneurysm no none OP none NA NA
Cheng et
al. [19]
F 58 liver tumor none no none OP+C/T none 14 M Factor VIII,
vimentin
DM = diabetes mellitus; HTN = hypertension; OA = osteoarthritis; CRI = chronic renal insufficiency; PUD = peptic ulcer disease; L/C = liver cirrhosis; OP =
operation; TAE = transarterial embolization; C/T = chemotherapy; R/T = readiotherapy; C = conservative treatment; M = month; W = week; D = day; NA = not
available.
Table 3 Laboratory data of patients of hepatic angiosarcoma
Variable All (n = 9) Men (n = 6) Women (n = 3) p value
WBC (/Cumm) 7461 ± 2785 5806 ± 1471 10770 ± 995 0.02
Hgb (g%) 12.1 ± 1.8 12.7 ± 2.0 10.8 ± 0.6 0.24
Platelet (k/Cumm) 176.2 ± 104.6 182.2 ± 73.2 164.3 ± 173.3 0.61
Blood Sugar (mg/dL) 147.3 ± 53.5 158.2 ± 63.9 125.7 ± 13.7 > 0.95
BUN (mg/dL) 14.0 ± 4.9 15.3 ± 5.3 14.4 ± 8.0 0.50
Creatinine (mg/dL) 1.7 ± 2.1 1.1 ± 0.2 3.0 ± 3.7 0.90
Sodium (mmol/L) 137.1 ± 2.5 138.0 ± 1.7 135.3 ± 3.2 0.24
Potasium (mmol/L) 3.9 ± 0.6 4.0 ± 0.4 3.8 ± 1.1 0.80
Calcium (mg/dL) 9.2 ± 0.7 9.0 ± 0.2 9.4 ± 1.4 > 0.95
T-Bilirubin (U/L) 3.4 ± 7.1 1.0 ± 0.6 10.8 ± 14.3 0.50
AST (U/L) 39.1 ± 17.9 42.3 ± 19.1 29.5 ± 13.4 0.40
ALT (U/L) 28.9 ± 17.5 32.5 ± 18.0 21.7 ± 17.4 0.44
ALP (U/L) 171.4 ± 77.4 164.0 ± 68.6 193.5 ± 130.8 0.74
rGT (U/L) 131.3 ± 23.2 120.0 ± 0.0 137.0 ± 29.7 > 0.95
CK (U/L) 47.0 ± 20.8 46.5 ± 14.8 47.3 ± 27.5 > 0.95
Amylase (U/L) 36.3 ± 8.5 38.0 ± 11.3 33.0 ± 0.0 > 0.95
Albumin (g/L) 3.5 ± 0.3 3.6 ± 0.3 3.5 ± 0.0 0.76
WBC = white cell count; Hgb = hemoglobulin; BUN = blood urea nitrogen; AST = aspartate aminotransferase; ALT = alanine aminotransferase; rGT = r-Glutamyl
Transpeptidase; CK = creatine kinase.
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wan, and two of them (one patient in our series and one
previously reported case [3]) received emergent surgical
intervention and survived for a period of time till
another life-threatening event that cost their lives. Emer-
gent surgery seems effective in the treatment of liver
rupture.
Early reports of HAS often focus on its associations
with environmental carcinogens such as VCM, arsenic
in pesticide or drinking water, thorium dioxide, radium,
and Fowler’s solution, but exposures to these agents
have become rare nowadays. Of the 135 patients
reported by Falk et al., 126 (75%) were attributed to
uncertain etiology [2]. Similarly, none of the nine
patients in the current study could be attributed to spe-
cific etiology, and of the nine previously reported cases
in Taiwan, only two were found to have chronic expo-
sure to arsenic pesticide or arsenic in drinking water. In
total, 15 of the 18 cases (83.3%) of HAS in Taiwan had
no known etiology.
Although HBV infection increases the risk of liver
cancer in VCM workers [26,27], none of the 18 cases
had exposure to VCM, and only one previously reported
patient had chronic HBV infection. Taiwan is an ende-
mic area of viral hepatitis, including HBV and HCV
infection. The reported seroprevalence of HBsAg ranged
from 15% to 20% in Taiwan [28-30], and the seropreva-
l e n c eo fH B Vw eo b s e r v e d( 5 . 6 % ;1i n1 8c a s e s )w a s
lower, which does not support HBV infection being a
risk factor of HAS. On the other hand, 2 of the 18
patients had HCV infection. More than 170 million peo-
ple worldwide are chronically infected with the HCV,
which causes over 1 million deaths resulting from cir-
rhosis and liver cancers [31]. The reported seropreva-
lence of anti-HCV has a very wide range in Taiwan
[32-35] and reached 60% in some townships in the
southwestern coast [34], which is higher than the preva-
lence we observed (11.1%, 2 in 18 cases). An association
between HCV and HAS has not been confirmed, and
further studies are necessary to clarify their relationship.
One of our cases had uremia, and we found another
c a s eo fH A Si nau r e m i ap a t i e n tw i t hah i s t o r yo fH C V
infection in the literature [4]. HCV infection is a signifi-
cant cause of morbidity and mortality in HD patients,
and the prevalence of HCV in HD population varies
from 1.9 to 84.6% [36]. A study in Taiwan observed an
anti-HCV seroprevalence of 33.2% in HD patients [37].
In previous studies, more than 70% of HAS patients
have multifocal or multinodular lesions [21,38], and
most of them have metastatic lesions at the time of pre-
sentation such as lung or splenic metastasis [1,38]. The
prognosis of patients with HAS is poor with a median
survival of around 6 months, and only 3% survived for
more than 2 years [1,2]. In our study, three patients
identified at the hospital and one previously reported
case had metastasis at the time of diagnosis. Three of
them received operation, and two received post opera-
tion chemotherapy. Consequently, three of our patients
and three reported patients lived for more than 2 years
(24, 37, and 44 months and 24, 42, and 42 months,
respectively), although some survived only 3 months
after diagnosis. Therefore, aggressive treatment may still
prolong the survival of patients with metastases.
Our study has a few limitations. First, this was a retro-
spective study, which limits the amount of data to be
collected. On the other hand, because all the 9 cases in
the literature were collected from case reports which
were also on the basis of medical records, information
on the 9 cases in our series and the 9 cases in the litera-
ture should be comparable. Second, the total number of
cases is small, which limits further analysis. Nonetheless,
together with cases reported previously, only a small
portion of the patients had exposures to arsenic or viral
hepatitis, and none had exposures to VCM, even though
these risk factors are relatively prevalent in Taiwan.
Conclusions
HAS is rare in Taiwan, and we found no evidence sup-
porting a major role of VCM, arsenic in drinking water,
or viral hepatitis in its occurrence. Further studies are
necessary to clarify the etiologies of HAS in Taiwan.
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